Burden of illness in hereditary periodic fevers: a multinational observational patient diary study.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 22 10 2019
accepted: 02 04 2020
pubmed: 8 10 2020
medline: 19 12 2020
entrez: 7 10 2020
Statut: ppublish

Résumé

This study aimed to characterise the burden of illness of patients with inadequately controlled hereditary periodic fevers (HPFs), during and outside of flares. It was focused on the burden to the patients and also considered the wider impact on their caregivers and families. The target population was patients or caregivers of patients with clinically/genetically confirmed colchicine resistant FMF (crFMF), mevalonate kinase deficiency/hyperimmunoglobinaemia D with periodic fever syndrome (MKD/HIDS) or TRAPS, who were expected to flare at least once in a 6-month period based on patient history. Disease burden was captured during and between flares using an electronic diary (e-diary) with questions on patient functioning, emotional/social well-being and pain, using validated instruments. HPF-related symptoms such as fever, joint, muscle or bone pain and tiredness and fatigue were reported by patients both during and outside of a flare. The SF-10 Health Survey (SF-10v2) (paediatric patients) and SF-12 Health Survey (SF-12v2) (adult patients) showed that flares negatively impacted patients' psychosocial and physical health. Negative effect of on-flare status on health utility index score assessed by the Short-Form Six-Dimension (SF-6D) was significant only for crFMF patients. Furthermore, the Sheehan Disability Score (SDSv3) showing the on-flare status resulted in significant functional impairment in all 3 disease cohorts through assessment of impact on work/school, social and family life. crFMF, MKD/HIDS and TRAPS negatively affected the quality of life (QoL) of adult and paediatric patients, including their physical, mental, psychosocial health, and social functioning. There remains, however, a high number of unmet needs for these patients to reduce their disease burden.

Identifiants

pubmed: 33025894
pii: 14906

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-34

Auteurs

Jasmin B Kuemmerle-Deschner (JB)

Division of Paediatric Rheumatology, Department of Paediatrics and Autoinflammation Reference Centre Tübingen, University Hospital Tübingen, Germany. jasmin.kuemmerle-deschner@med.uni-tuebingen.de.

Pierre Quartier (P)

Paris-University, IMAGINE Institute, Rare Disease Reference Centre RAISE, Necker-Enfants Malades Hospital, Assistance Publique-Hopitaux de Paris, France.

Isabelle Kone-Paut (I)

Paediatric Rheumatology and CEREMAIA, Le Kremlin-Bicêtre University Hospital, APHP, Paris-Sud University, France.

Veronique Hentgen (V)

French Reference Centre for Autoinflammatory Diseases and Secondary Amyloidosis (CEREMAIA), Versailles Hospital-Le Chesnay, Paris, France.

Katherine Anne Marzan (KA)

Paediatric Rheumatology Children's Hospital Los Angeles, Keck School of Medicine USC, Los Angeles, CA, USA.

Fatma Dedeoglu (F)

Division of Immunology, Rheumatology Program, Boston Children's Hospital, Department of Paediatrics, Harvard Medical School, Boston, MA, USA.

Helen Jane Lachmann (HJ)

National Amyloidosis Centre and Centre for Acute Phase Proteins, Division of Medicine, University College London and Royal Free Hospital London NHS Foundation Trust, London, UK.

Tilman Kallinich (T)

Department of Paediatric Pneumology and Immunology, Charité Medical University of Berlin, Germany.

Norbert Blank (N)

Division of Rheumatology, University Hospital, Heidelberg, Germany.

Seza Ozen (S)

Department of Paediatric Rheumatology, Hacettepe University, Ankara, Turkey.

Yelda Bilginer (Y)

Department of Paediatric Rheumatology, Hacettepe University, Ankara, Turkey.

Jonathan S Hausmann (JS)

Division of Immunology, Rheumatology Program, Boston Children's Hospital, Department of Paediatrics, Harvard Medical School, Boston, MA, and Division of Rheumatology, Autoinflammatory Diseases Centre, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston MA, USA.

Arturo Diaz (A)

Division of Rheumatology, Autoinflammatory Diseases Centre, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA.

Maurice Perrinjaquet (M)

Navigant Life Sciences, Berlin, Germany.

Nina Marinsek (N)

Navigant Life Sciences, London, UK.

Kathleen G Lomax (KG)

Novartis Pharmaceuticals Corporation, NJ, USA.

Peter Hur (P)

Novartis Pharmaceuticals Corporation, NJ, USA.

Elise L Dekker (EL)

Novartis Pharmaceuticals Corporation, NJ, USA.

Avi Livneh (A)

Medicine F, Sheba Medical Centre, Tel-Hashomer, Ramat-Gan, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH